nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—SLC6A2—locus ceruleus—Alzheimer's disease	0.034	0.144	CbGeAlD
Droxidopa—DDC—telencephalic ventricle—Alzheimer's disease	0.0339	0.143	CbGeAlD
Droxidopa—Hyperpyrexia—Rivastigmine—Alzheimer's disease	0.0295	0.107	CcSEcCtD
Droxidopa—Myocardial ischaemia—Galantamine—Alzheimer's disease	0.0199	0.0722	CcSEcCtD
Droxidopa—Myocardial ischaemia—Rivastigmine—Alzheimer's disease	0.0137	0.0497	CcSEcCtD
Droxidopa—DDC—embryo—Alzheimer's disease	0.01	0.0423	CbGeAlD
Droxidopa—Cardiac failure congestive—Donepezil—Alzheimer's disease	0.00991	0.036	CcSEcCtD
Droxidopa—Cardiac failure congestive—Memantine—Alzheimer's disease	0.009	0.0327	CcSEcCtD
Droxidopa—DDC—forebrain—Alzheimer's disease	0.00885	0.0374	CbGeAlD
Droxidopa—Urinary tract infection—Galantamine—Alzheimer's disease	0.00869	0.0315	CcSEcCtD
Droxidopa—PAH—nervous system—Alzheimer's disease	0.00843	0.0356	CbGeAlD
Droxidopa—DDC—telencephalon—Alzheimer's disease	0.00814	0.0344	CbGeAlD
Droxidopa—PAH—central nervous system—Alzheimer's disease	0.00811	0.0343	CbGeAlD
Droxidopa—Arrhythmia—Galantamine—Alzheimer's disease	0.00717	0.026	CcSEcCtD
Droxidopa—ADRA1D—forebrain—Alzheimer's disease	0.00682	0.0288	CbGeAlD
Droxidopa—Urinary tract infection—Donepezil—Alzheimer's disease	0.00673	0.0244	CcSEcCtD
Droxidopa—PAH—brain—Alzheimer's disease	0.00644	0.0272	CbGeAlD
Droxidopa—ADRA1D—telencephalon—Alzheimer's disease	0.00628	0.0265	CbGeAlD
Droxidopa—Syncope—Galantamine—Alzheimer's disease	0.00626	0.0227	CcSEcCtD
Droxidopa—Loss of consciousness—Galantamine—Alzheimer's disease	0.00614	0.0223	CcSEcCtD
Droxidopa—Urinary tract infection—Memantine—Alzheimer's disease	0.00611	0.0222	CcSEcCtD
Droxidopa—Hypertension—Galantamine—Alzheimer's disease	0.00603	0.0219	CcSEcCtD
Droxidopa—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.00598	0.0217	CcSEcCtD
Droxidopa—Confusional state—Galantamine—Alzheimer's disease	0.00575	0.0209	CcSEcCtD
Droxidopa—Shock—Galantamine—Alzheimer's disease	0.00561	0.0204	CcSEcCtD
Droxidopa—Arrhythmia—Donepezil—Alzheimer's disease	0.00556	0.0202	CcSEcCtD
Droxidopa—Arrhythmia—Memantine—Alzheimer's disease	0.00504	0.0183	CcSEcCtD
Droxidopa—ADRB1—forebrain—Alzheimer's disease	0.00496	0.0209	CbGeAlD
Droxidopa—Arrhythmia—Rivastigmine—Alzheimer's disease	0.00493	0.0179	CcSEcCtD
Droxidopa—Syncope—Donepezil—Alzheimer's disease	0.00485	0.0176	CcSEcCtD
Droxidopa—DDC—nervous system—Alzheimer's disease	0.0048	0.0203	CbGeAlD
Droxidopa—Loss of consciousness—Donepezil—Alzheimer's disease	0.00476	0.0173	CcSEcCtD
Droxidopa—Feeling abnormal—Galantamine—Alzheimer's disease	0.0047	0.0171	CcSEcCtD
Droxidopa—Hypertension—Donepezil—Alzheimer's disease	0.00467	0.017	CcSEcCtD
Droxidopa—DDC—central nervous system—Alzheimer's disease	0.00463	0.0195	CbGeAlD
Droxidopa—ADRB1—telencephalon—Alzheimer's disease	0.00456	0.0193	CbGeAlD
Droxidopa—Confusional state—Donepezil—Alzheimer's disease	0.00445	0.0162	CcSEcCtD
Droxidopa—Syncope—Memantine—Alzheimer's disease	0.00441	0.016	CcSEcCtD
Droxidopa—Shock—Donepezil—Alzheimer's disease	0.00435	0.0158	CcSEcCtD
Droxidopa—Loss of consciousness—Memantine—Alzheimer's disease	0.00432	0.0157	CcSEcCtD
Droxidopa—Syncope—Rivastigmine—Alzheimer's disease	0.00431	0.0157	CcSEcCtD
Droxidopa—Hypertension—Memantine—Alzheimer's disease	0.00424	0.0154	CcSEcCtD
Droxidopa—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.00423	0.0153	CcSEcCtD
Droxidopa—SLC6A2—forebrain—Alzheimer's disease	0.00422	0.0178	CbGeAlD
Droxidopa—Hypertension—Rivastigmine—Alzheimer's disease	0.00415	0.0151	CcSEcCtD
Droxidopa—Confusional state—Memantine—Alzheimer's disease	0.00404	0.0147	CcSEcCtD
Droxidopa—Confusional state—Rivastigmine—Alzheimer's disease	0.00396	0.0144	CcSEcCtD
Droxidopa—Shock—Memantine—Alzheimer's disease	0.00395	0.0143	CcSEcCtD
Droxidopa—ADRA1A—forebrain—Alzheimer's disease	0.00392	0.0166	CbGeAlD
Droxidopa—SLC6A2—telencephalon—Alzheimer's disease	0.00388	0.0164	CbGeAlD
Droxidopa—Shock—Rivastigmine—Alzheimer's disease	0.00386	0.014	CcSEcCtD
Droxidopa—ADRA1B—nervous system—Alzheimer's disease	0.00379	0.016	CbGeAlD
Droxidopa—Dizziness—Galantamine—Alzheimer's disease	0.00377	0.0137	CcSEcCtD
Droxidopa—ADRA1D—nervous system—Alzheimer's disease	0.0037	0.0157	CbGeAlD
Droxidopa—DDC—brain—Alzheimer's disease	0.00367	0.0155	CbGeAlD
Droxidopa—ADRA1B—central nervous system—Alzheimer's disease	0.00365	0.0154	CbGeAlD
Droxidopa—Feeling abnormal—Donepezil—Alzheimer's disease	0.00364	0.0132	CcSEcCtD
Droxidopa—ADRA1A—telencephalon—Alzheimer's disease	0.0036	0.0152	CbGeAlD
Droxidopa—Headache—Galantamine—Alzheimer's disease	0.00357	0.013	CcSEcCtD
Droxidopa—ADRA1D—central nervous system—Alzheimer's disease	0.00357	0.0151	CbGeAlD
Droxidopa—ADRA2C—telencephalon—Alzheimer's disease	0.00343	0.0145	CbGeAlD
Droxidopa—Nausea—Galantamine—Alzheimer's disease	0.00339	0.0123	CcSEcCtD
Droxidopa—Feeling abnormal—Memantine—Alzheimer's disease	0.00331	0.012	CcSEcCtD
Droxidopa—Aminosalicylic Acid—MPO—Alzheimer's disease	0.00328	0.165	CrCbGaD
Droxidopa—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.00323	0.0117	CcSEcCtD
Droxidopa—SLC16A10—cerebellum—Alzheimer's disease	0.0031	0.0131	CbGeAlD
Droxidopa—ADRA2A—forebrain—Alzheimer's disease	0.00298	0.0126	CbGeAlD
Droxidopa—Dizziness—Donepezil—Alzheimer's disease	0.00292	0.0106	CcSEcCtD
Droxidopa—ADRA1B—brain—Alzheimer's disease	0.00289	0.0122	CbGeAlD
Droxidopa—ADRA1D—brain—Alzheimer's disease	0.00283	0.012	CbGeAlD
Droxidopa—Headache—Donepezil—Alzheimer's disease	0.00277	0.01	CcSEcCtD
Droxidopa—ADRA2A—telencephalon—Alzheimer's disease	0.00274	0.0116	CbGeAlD
Droxidopa—ADRB1—nervous system—Alzheimer's disease	0.00269	0.0114	CbGeAlD
Droxidopa—Dizziness—Memantine—Alzheimer's disease	0.00265	0.00963	CcSEcCtD
Droxidopa—Nausea—Donepezil—Alzheimer's disease	0.00262	0.00953	CcSEcCtD
Droxidopa—Dizziness—Rivastigmine—Alzheimer's disease	0.00259	0.00942	CcSEcCtD
Droxidopa—ADRB1—central nervous system—Alzheimer's disease	0.00259	0.0109	CbGeAlD
Droxidopa—Mesalazine—MPO—Alzheimer's disease	0.00257	0.13	CrCbGaD
Droxidopa—Headache—Memantine—Alzheimer's disease	0.00251	0.00912	CcSEcCtD
Droxidopa—Headache—Rivastigmine—Alzheimer's disease	0.00246	0.00893	CcSEcCtD
Droxidopa—Nausea—Memantine—Alzheimer's disease	0.00238	0.00865	CcSEcCtD
Droxidopa—Nausea—Rivastigmine—Alzheimer's disease	0.00233	0.00846	CcSEcCtD
Droxidopa—SLC6A2—nervous system—Alzheimer's disease	0.00229	0.00967	CbGeAlD
Droxidopa—Mesalazine—PPARG—Alzheimer's disease	0.00228	0.115	CrCbGaD
Droxidopa—SLC6A2—central nervous system—Alzheimer's disease	0.0022	0.00931	CbGeAlD
Droxidopa—Aminosalicylic Acid—PTGS1—Alzheimer's disease	0.00215	0.108	CrCbGaD
Droxidopa—Dopamine—MAOB—Alzheimer's disease	0.00213	0.107	CrCbGaD
Droxidopa—ADRA1A—nervous system—Alzheimer's disease	0.00213	0.00899	CbGeAlD
Droxidopa—ADRB1—brain—Alzheimer's disease	0.00206	0.00869	CbGeAlD
Droxidopa—ADRA1A—central nervous system—Alzheimer's disease	0.00205	0.00865	CbGeAlD
Droxidopa—ADRA2C—nervous system—Alzheimer's disease	0.00203	0.00857	CbGeAlD
Droxidopa—ADRA1A—cerebellum—Alzheimer's disease	0.002	0.00846	CbGeAlD
Droxidopa—ADRA2C—central nervous system—Alzheimer's disease	0.00195	0.00825	CbGeAlD
Droxidopa—ADRA2C—cerebellum—Alzheimer's disease	0.00191	0.00806	CbGeAlD
Droxidopa—SLC6A2—brain—Alzheimer's disease	0.00175	0.00739	CbGeAlD
Droxidopa—Mesalazine—PTGS1—Alzheimer's disease	0.00169	0.085	CrCbGaD
Droxidopa—ADRA1A—brain—Alzheimer's disease	0.00163	0.00687	CbGeAlD
Droxidopa—ADRA2A—nervous system—Alzheimer's disease	0.00162	0.00684	CbGeAlD
Droxidopa—ADRA2A—central nervous system—Alzheimer's disease	0.00156	0.00658	CbGeAlD
Droxidopa—ADRA2C—brain—Alzheimer's disease	0.00155	0.00655	CbGeAlD
Droxidopa—ADRA2A—cerebellum—Alzheimer's disease	0.00152	0.00643	CbGeAlD
Droxidopa—ADRA2A—brain—Alzheimer's disease	0.00124	0.00522	CbGeAlD
Droxidopa—Aminosalicylic Acid—PTGS2—Alzheimer's disease	0.00123	0.0619	CrCbGaD
Droxidopa—Epinephrine—TNF—Alzheimer's disease	0.00117	0.0589	CrCbGaD
Droxidopa—Mesalazine—PTGS2—Alzheimer's disease	0.000964	0.0486	CrCbGaD
Droxidopa—Dopamine—SLC6A4—Alzheimer's disease	0.000964	0.0486	CrCbGaD
Droxidopa—L-DOPA—CYP2D6—Alzheimer's disease	0.000729	0.0367	CrCbGaD
Droxidopa—Dopamine—CYP2D6—Alzheimer's disease	0.000677	0.0342	CrCbGaD
Droxidopa—ADRA1D—Signaling Pathways—LEP—Alzheimer's disease	3.41e-05	7.29e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CAV1—Alzheimer's disease	3.41e-05	7.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MEF2C—Alzheimer's disease	3.4e-05	7.27e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—S100B—Alzheimer's disease	3.4e-05	7.26e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CREB1—Alzheimer's disease	3.4e-05	7.26e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCR5—Alzheimer's disease	3.38e-05	7.23e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CAV1—Alzheimer's disease	3.38e-05	7.22e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—LPL—Alzheimer's disease	3.38e-05	7.21e-05	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—AKT1—Alzheimer's disease	3.36e-05	7.18e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MEF2C—Alzheimer's disease	3.35e-05	7.15e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—Alzheimer's disease	3.34e-05	7.14e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCR5—Alzheimer's disease	3.34e-05	7.14e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ADAM10—Alzheimer's disease	3.34e-05	7.13e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PRKCG—Alzheimer's disease	3.34e-05	7.13e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—LPL—Alzheimer's disease	3.33e-05	7.12e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CASP3—Alzheimer's disease	3.33e-05	7.11e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCL2—Alzheimer's disease	3.32e-05	7.1e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—Alzheimer's disease	3.31e-05	7.08e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—IL6—Alzheimer's disease	3.31e-05	7.07e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PRKCG—Alzheimer's disease	3.28e-05	7.02e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—Alzheimer's disease	3.27e-05	6.99e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ESR1—Alzheimer's disease	3.26e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NGF—Alzheimer's disease	3.25e-05	6.94e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IGF2—Alzheimer's disease	3.24e-05	6.91e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—F2—Alzheimer's disease	3.22e-05	6.87e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NGF—Alzheimer's disease	3.2e-05	6.83e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCR5—Alzheimer's disease	3.16e-05	6.75e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—S100B—Alzheimer's disease	3.16e-05	6.75e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NOTCH1—Alzheimer's disease	3.15e-05	6.72e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IGF1R—Alzheimer's disease	3.13e-05	6.68e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—AKT1—Alzheimer's disease	3.13e-05	6.68e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CALM1—Alzheimer's disease	3.12e-05	6.66e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCR5—Alzheimer's disease	3.11e-05	6.65e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—LEP—Alzheimer's disease	3.11e-05	6.64e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—APOE—Alzheimer's disease	3.11e-05	6.64e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—Alzheimer's disease	3.09e-05	6.61e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CALM1—Alzheimer's disease	3.09e-05	6.6e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—APOE—Alzheimer's disease	3.08e-05	6.58e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—LEP—Alzheimer's disease	3.08e-05	6.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CAV1—Alzheimer's disease	3.08e-05	6.58e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MAPK8—Alzheimer's disease	3.06e-05	6.54e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—AKT1—Alzheimer's disease	3.05e-05	6.52e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CAV1—Alzheimer's disease	3.05e-05	6.52e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CALM1—Alzheimer's disease	3.05e-05	6.52e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—Alzheimer's disease	3.04e-05	6.51e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—APOE—Alzheimer's disease	3.04e-05	6.49e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—LEP—Alzheimer's disease	3.04e-05	6.49e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CAV1—Alzheimer's disease	3.01e-05	6.43e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF2—Alzheimer's disease	3.01e-05	6.42e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—MTHFR—Alzheimer's disease	3e-05	6.41e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—LPL—Alzheimer's disease	3e-05	6.41e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PPARG—Alzheimer's disease	3e-05	6.4e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MEF2C—Alzheimer's disease	2.97e-05	6.35e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ESR1—Alzheimer's disease	2.97e-05	6.34e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—GSK3B—Alzheimer's disease	2.95e-05	6.31e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ESR1—Alzheimer's disease	2.94e-05	6.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—INS—Alzheimer's disease	2.94e-05	6.28e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—F2—Alzheimer's disease	2.93e-05	6.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CREB1—Alzheimer's disease	2.93e-05	6.26e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—AKT1—Alzheimer's disease	2.92e-05	6.24e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PRKCG—Alzheimer's disease	2.92e-05	6.23e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—INS—Alzheimer's disease	2.91e-05	6.22e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF1R—Alzheimer's disease	2.91e-05	6.21e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—F2—Alzheimer's disease	2.9e-05	6.2e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ESR1—Alzheimer's disease	2.9e-05	6.2e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CALM1—Alzheimer's disease	2.89e-05	6.17e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—APOE—Alzheimer's disease	2.88e-05	6.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—LEP—Alzheimer's disease	2.88e-05	6.14e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NOTCH1—Alzheimer's disease	2.87e-05	6.13e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL2—Alzheimer's disease	2.87e-05	6.12e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—F2—Alzheimer's disease	2.87e-05	6.12e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CAV1—Alzheimer's disease	2.85e-05	6.09e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NOTCH1—Alzheimer's disease	2.84e-05	6.07e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NGF—Alzheimer's disease	2.84e-05	6.07e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CALM1—Alzheimer's disease	2.84e-05	6.07e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—LEP—Alzheimer's disease	2.83e-05	6.05e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—APOE—Alzheimer's disease	2.83e-05	6.05e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—VEGFA—Alzheimer's disease	2.83e-05	6.04e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IGF1—Alzheimer's disease	2.82e-05	6.02e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—TP53—Alzheimer's disease	2.81e-05	6e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NOTCH1—Alzheimer's disease	2.81e-05	5.99e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CAV1—Alzheimer's disease	2.8e-05	5.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CALM1—Alzheimer's disease	2.8e-05	5.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—APOE—Alzheimer's disease	2.79e-05	5.97e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—LPL—Alzheimer's disease	2.79e-05	5.95e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CAV1—Alzheimer's disease	2.77e-05	5.91e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCR5—Alzheimer's disease	2.76e-05	5.9e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MEF2C—Alzheimer's disease	2.76e-05	5.9e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ESR1—Alzheimer's disease	2.75e-05	5.87e-05	CbGpPWpGaD
Droxidopa—DDC—Metabolism—AKT1—Alzheimer's disease	2.73e-05	5.83e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—F2—Alzheimer's disease	2.71e-05	5.79e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PRKCG—Alzheimer's disease	2.71e-05	5.79e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—Alzheimer's disease	2.7e-05	5.78e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ESR1—Alzheimer's disease	2.7e-05	5.77e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GSK3B—Alzheimer's disease	2.69e-05	5.75e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CREB1—Alzheimer's disease	2.67e-05	5.7e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—F2—Alzheimer's disease	2.67e-05	5.7e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GSK3B—Alzheimer's disease	2.67e-05	5.7e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—INS—Alzheimer's disease	2.65e-05	5.67e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NOTCH1—Alzheimer's disease	2.65e-05	5.67e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CREB1—Alzheimer's disease	2.65e-05	5.65e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NGF—Alzheimer's disease	2.64e-05	5.64e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GSK3B—Alzheimer's disease	2.63e-05	5.62e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—INS—Alzheimer's disease	2.63e-05	5.62e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NOTCH1—Alzheimer's disease	2.61e-05	5.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL2—Alzheimer's disease	2.61e-05	5.58e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CREB1—Alzheimer's disease	2.61e-05	5.58e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—INS—Alzheimer's disease	2.6e-05	5.55e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TGFB1—Alzheimer's disease	2.59e-05	5.54e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL2—Alzheimer's disease	2.59e-05	5.53e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—NOS3—Alzheimer's disease	2.58e-05	5.51e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCR5—Alzheimer's disease	2.57e-05	5.49e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IGF1—Alzheimer's disease	2.57e-05	5.49e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL2—Alzheimer's disease	2.56e-05	5.46e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NOS3—Alzheimer's disease	2.56e-05	5.46e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IGF1—Alzheimer's disease	2.54e-05	5.44e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CALM1—Alzheimer's disease	2.52e-05	5.39e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APOE—Alzheimer's disease	2.51e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—LEP—Alzheimer's disease	2.51e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—Alzheimer's disease	2.51e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IGF1—Alzheimer's disease	2.51e-05	5.37e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CAV1—Alzheimer's disease	2.49e-05	5.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GSK3B—Alzheimer's disease	2.49e-05	5.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CREB1—Alzheimer's disease	2.47e-05	5.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—INS—Alzheimer's disease	2.46e-05	5.25e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GSK3B—Alzheimer's disease	2.45e-05	5.24e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PPARG—Alzheimer's disease	2.43e-05	5.2e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CREB1—Alzheimer's disease	2.43e-05	5.2e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—INS—Alzheimer's disease	2.42e-05	5.17e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL2—Alzheimer's disease	2.42e-05	5.16e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ESR1—Alzheimer's disease	2.4e-05	5.13e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—INS—Alzheimer's disease	2.39e-05	5.1e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL2—Alzheimer's disease	2.38e-05	5.08e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IGF1—Alzheimer's disease	2.38e-05	5.08e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—AKT1—Alzheimer's disease	2.37e-05	5.07e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—F2—Alzheimer's disease	2.37e-05	5.07e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTGS2—Alzheimer's disease	2.36e-05	5.04e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CALM1—Alzheimer's disease	2.34e-05	5.01e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IGF1—Alzheimer's disease	2.34e-05	5e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—LEP—Alzheimer's disease	2.34e-05	4.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APOE—Alzheimer's disease	2.34e-05	4.99e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NOS3—Alzheimer's disease	2.33e-05	4.97e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NOTCH1—Alzheimer's disease	2.32e-05	4.96e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CAV1—Alzheimer's disease	2.31e-05	4.95e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NOS3—Alzheimer's disease	2.31e-05	4.93e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NOS3—Alzheimer's disease	2.28e-05	4.87e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ESR1—Alzheimer's disease	2.23e-05	4.77e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—F2—Alzheimer's disease	2.2e-05	4.71e-05	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—AKT1—Alzheimer's disease	2.19e-05	4.68e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GSK3B—Alzheimer's disease	2.18e-05	4.65e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CASP3—Alzheimer's disease	2.17e-05	4.63e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CREB1—Alzheimer's disease	2.16e-05	4.61e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NOTCH1—Alzheimer's disease	2.16e-05	4.61e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—IL6—Alzheimer's disease	2.16e-05	4.6e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NOS3—Alzheimer's disease	2.15e-05	4.6e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—INS—Alzheimer's disease	2.15e-05	4.59e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—Alzheimer's disease	2.14e-05	4.56e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NOS3—Alzheimer's disease	2.12e-05	4.53e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL2—Alzheimer's disease	2.11e-05	4.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—NOS3—Alzheimer's disease	2.09e-05	4.47e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IGF1—Alzheimer's disease	2.08e-05	4.44e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GSK3B—Alzheimer's disease	2.02e-05	4.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CREB1—Alzheimer's disease	2.01e-05	4.29e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—INS—Alzheimer's disease	2e-05	4.26e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—Alzheimer's disease	1.99e-05	4.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MAPK8—Alzheimer's disease	1.99e-05	4.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—Alzheimer's disease	1.99e-05	4.25e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—Alzheimer's disease	1.98e-05	4.22e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CASP3—Alzheimer's disease	1.98e-05	4.22e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—Alzheimer's disease	1.96e-05	4.2e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL2—Alzheimer's disease	1.96e-05	4.2e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CASP3—Alzheimer's disease	1.96e-05	4.18e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—Alzheimer's disease	1.95e-05	4.18e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—Alzheimer's disease	1.95e-05	4.17e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—Alzheimer's disease	1.95e-05	4.16e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CASP3—Alzheimer's disease	1.93e-05	4.13e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF1—Alzheimer's disease	1.93e-05	4.12e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—Alzheimer's disease	1.92e-05	4.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—Alzheimer's disease	1.91e-05	4.09e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NOS3—Alzheimer's disease	1.88e-05	4.02e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—Alzheimer's disease	1.85e-05	3.94e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—Alzheimer's disease	1.84e-05	3.93e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CASP3—Alzheimer's disease	1.83e-05	3.91e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—Alzheimer's disease	1.82e-05	3.88e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—Alzheimer's disease	1.82e-05	3.88e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MAPK8—Alzheimer's disease	1.82e-05	3.88e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—Alzheimer's disease	1.81e-05	3.87e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—Alzheimer's disease	1.8e-05	3.85e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CASP3—Alzheimer's disease	1.8e-05	3.85e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MAPK8—Alzheimer's disease	1.8e-05	3.85e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—Alzheimer's disease	1.79e-05	3.83e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—Alzheimer's disease	1.79e-05	3.82e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MAPK8—Alzheimer's disease	1.78e-05	3.8e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—Alzheimer's disease	1.77e-05	3.79e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NOS3—Alzheimer's disease	1.75e-05	3.74e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TGFB1—Alzheimer's disease	1.69e-05	3.61e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MAPK8—Alzheimer's disease	1.68e-05	3.59e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—Alzheimer's disease	1.68e-05	3.58e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—Alzheimer's disease	1.68e-05	3.58e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—Alzheimer's disease	1.66e-05	3.55e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MAPK8—Alzheimer's disease	1.65e-05	3.54e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—Alzheimer's disease	1.65e-05	3.53e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—Alzheimer's disease	1.64e-05	3.51e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—Alzheimer's disease	1.61e-05	3.45e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CASP3—Alzheimer's disease	1.6e-05	3.42e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—Alzheimer's disease	1.59e-05	3.39e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—Alzheimer's disease	1.55e-05	3.32e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TGFB1—Alzheimer's disease	1.54e-05	3.29e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—Alzheimer's disease	1.53e-05	3.26e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TGFB1—Alzheimer's disease	1.53e-05	3.26e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TGFB1—Alzheimer's disease	1.51e-05	3.22e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—Alzheimer's disease	1.5e-05	3.2e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CASP3—Alzheimer's disease	1.49e-05	3.17e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—Alzheimer's disease	1.48e-05	3.15e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAPK8—Alzheimer's disease	1.47e-05	3.14e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—Alzheimer's disease	1.47e-05	3.13e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TGFB1—Alzheimer's disease	1.42e-05	3.04e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TGFB1—Alzheimer's disease	1.4e-05	3e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—Alzheimer's disease	1.39e-05	2.97e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAPK8—Alzheimer's disease	1.37e-05	2.92e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—Alzheimer's disease	1.36e-05	2.91e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—Alzheimer's disease	1.36e-05	2.9e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—Alzheimer's disease	1.27e-05	2.72e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—Alzheimer's disease	1.27e-05	2.71e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—Alzheimer's disease	1.26e-05	2.69e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—Alzheimer's disease	1.26e-05	2.68e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TGFB1—Alzheimer's disease	1.25e-05	2.66e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—Alzheimer's disease	1.24e-05	2.65e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—Alzheimer's disease	1.18e-05	2.53e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—Alzheimer's disease	1.17e-05	2.51e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—Alzheimer's disease	1.17e-05	2.51e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—Alzheimer's disease	1.16e-05	2.48e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.16e-05	2.47e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—Alzheimer's disease	1.15e-05	2.47e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—Alzheimer's disease	1.15e-05	2.46e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—Alzheimer's disease	1.13e-05	2.42e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—Alzheimer's disease	1.07e-05	2.29e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—Alzheimer's disease	1.07e-05	2.29e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—Alzheimer's disease	1.06e-05	2.27e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—Alzheimer's disease	1.06e-05	2.26e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—Alzheimer's disease	1.05e-05	2.24e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—Alzheimer's disease	1.03e-05	2.19e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—Alzheimer's disease	9.9e-06	2.12e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—Alzheimer's disease	9.75e-06	2.08e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—Alzheimer's disease	9.62e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—Alzheimer's disease	9.53e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—Alzheimer's disease	9.39e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—Alzheimer's disease	8.72e-06	1.86e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—Alzheimer's disease	8.66e-06	1.85e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—Alzheimer's disease	8.05e-06	1.72e-05	CbGpPWpGaD
